// App-Quantinova.ai

: Serial Assessment of Cardiac Biomarkers and Risk of Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58

Researchers

Presenter

  • David D Berg

Principal Investigators

  • Stephen D Wiviott

  • Itamar Raz

  • Petr Jarolim

  • Erica Goodrich

  • ofri Mosenzon

  • Avivit Cahn

  • Deepak Bhatt

  • Lawrence Leiter

  • Darren K McGuire

  • JOHN WILDING

  • Ingrid A Gause-nilsson

  • Marc S Sabatine

  • David A Morrow

Medical Centers

  • UT Southwestern, Dallas, TX

  • Hadassah-Hebrew University, Jerusalem, Israel

  • Brigham & Women's Hospital, Boston, MA

  • St. Michael's Hosp, Toronto, ON, Canada

  • TIMI Study Group, Boston, MA

  • DIABETES MEDICAL CENTER, Tel Aviv, Israel

  • ASTRAZENECA, M Lndal, Sweden

  • HADASSAH HEBREW UNIVERCITY HOSPITAL, Jerusalem, Israel

  • BRIGHAM AND WOMENS HOSPITAL, Boston, MA

  • Brigham & Women's Hospital, Boston, MA

  • Univ of Liverpool, LIVERPOOL

Locations

  • Israel

  • Canada

  • United States

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Genetic Disorder

  • Central Nervous System (CNS)

Disease

  • Ischemic stroke

  • Congestive heart failure

  • Dyslipidemia

  • Hypertension

  • Stroke

Biomarkers

  • Body mass index

  • N-terminal pro b-type natriuretic peptide

  • High-sensitivity cardiac troponin T

Drug/Treatment

  • Dapagliflozin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved